Compare BLFS & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLFS | GAM |
|---|---|---|
| Founded | 1987 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1989 | N/A |
| Metric | BLFS | GAM |
|---|---|---|
| Price | $24.38 | $58.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | ★ 336.2K | 20.1K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | ★ $100,144,000.00 | N/A |
| Revenue This Year | $20.67 | N/A |
| Revenue Next Year | $14.13 | N/A |
| P/E Ratio | ★ N/A | $3.95 |
| Revenue Growth | ★ 87.53 | N/A |
| 52 Week Low | $19.10 | $37.32 |
| 52 Week High | $29.62 | $46.48 |
| Indicator | BLFS | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 41.49 |
| Support Level | $24.44 | $58.00 |
| Resistance Level | $25.96 | $59.22 |
| Average True Range (ATR) | 0.87 | 0.74 |
| MACD | -0.08 | 0.17 |
| Stochastic Oscillator | 4.36 | 65.60 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.